Abstracts tagged "patient-reported outcome measures"

Abstract Number: 1375 • 2019 ACR/ARP Annual Meeting
Patient-Reported Outcomes of Upadacitinib versus Adalimumab Use in Patients with Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate: 26-Week Analysis of a Phase 3 Study
Roy Fleischmann¹, Martin Bergman ², Namita Tundia ³, In-Ho Song ⁴, Jessica Suboticki ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Drexel University College of Medicine, Stockholm, Sweden, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: In patients with active rheumatoid arthritis (RA), 12-week treatment with upadacitinib (UPA) while on background MTX therapy resulted in significant and clinically meaningful improvements…
Abstract Number: 431 • 2019 ACR/ARP Annual Meeting
Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis
Michiel Luijten ¹, Caroline Terwee ², Hedy van Oers ², Mala Joosten ³, Merlijn van den Berg ², Dieneke Schonenberg-Meinema ², Koert Dolman ⁴, Rebecca Ten Cate ⁵, Leo Roorda ⁶, Martha Grootenhuis ³, Marion van Rossum⁷ and Lotte Haverman ², ¹Amsterdam University Medical Centers, Amsterdam, Noord-Holland, Netherlands, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands, ⁴Onze Lieve Vrouwe Gasthuis West, Amsterdam, Netherlands, ⁵Leiden University Medical Centre, Leiden, Netherlands, ⁶Amsterdam Rehabilitation Research Center | Reade, Amsterdam, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam
Background/Purpose: Patient-reported outcome measures (PROMs) are often used to include the patients perspective on treatment (outcome). However, the choice of PROMs is difficult, as there…
Abstract Number: 1376 • 2019 ACR/ARP Annual Meeting
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials
Vibeke Strand¹, Namita Tundia ², Alan Friedman ³, Heidi Camp ², Jessica Suboticki ⁴, Debbie Goldschmidt ⁵, Catherine Fernan ⁵ and Martin Bergman ⁶, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵Analysis Group, Inc., New York, NY, ⁶Drexel University College of Medicine, Stockholm, Sweden
Background/Purpose: Treatment with upadacitinib (UPA) monotherapy, a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week…
Abstract Number: 329 • 2018 ACR/ARHP Annual Meeting
Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures
Elisheva Weinberger¹, Douglas Einstadter² and Marina Magrey¹, ¹Rheumatology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: “Treat to target” is the goal of therapy in the treatment of Rheumatoid Arthritis (RA) based on the 2015 American College of Rheumatology (ACR)…
Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Dimitrios A. Pappas^1,2, Namita Tundia³, Ying Shan², Heather J Litman² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
Abstract Number: 892 • 2018 ACR/ARHP Annual Meeting
Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Nicolas Richard¹, Nigil Haroon², George Tomlinson³, Ismail Sari¹, Zahi Touma⁴ and Robert D Inman¹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects…
Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting
Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients
Jens Gert Kuipers¹, Michael Koller², Ulrich Rueffer³, Florian Zeman², Karolina Mueller⁴ and Joachim Weis⁵, ¹Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³German Fatigue Society, Cologne, Germany, ⁴Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁵University Clinic Centre Freiburg, Freiburg, Germany
Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Ana-Maria Orbai¹, Jessica Walsh², Peter Nash³, Lichen Teng⁴, Benoit Guerette⁴ and Rieke Alten⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ³University of Queensland, Brisbane, Australia, ⁴Celgene Corporation, Summit, NJ, ⁵Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Elizabeth Lee¹⁰, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
Richard Zogala¹, Karla Criner², Maria A. Lopez-Olivo¹, Natalia Zamora³, Devesh Rai¹, Gregory Pratt⁴, Jude K. A. des Bordes¹, Robin Christensen⁵ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Internal Medicine, Baylor College of Medicine, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark
Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Rebecca Heijke¹, Mathilda Björk¹, Martina Frodlund¹, Laura McDonald², Evo Alemao³ and Christopher Sjöwall¹, ¹Linköping University, Linköping, Sweden, ²Bristol-Myers Squibb, Uxbridge, United Kingdom, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Vibeke Strand¹, Rita Ganguly², Nan Li³, Prasheen Agarwal³, Shihong Sheng³, Kaiyin Fei³, Kelly McQuarrie³ and Sharon Popik³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²GlaxoSmithKline, Collegeville, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases. Effects of sirukumab on RA symptoms…
Abstract Number: 2242 • 2017 ACR/ARHP Annual Meeting
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Rong Mu¹, Jing Yang², Hua Wei³, Wenqiang Fan⁴, Jianlin Huang⁵, Hongzhi Wang⁶, Jinli Ru⁷, Yongfu Wang⁸, Jinmei Zou², Jianling Dong², Xinwang Duan⁹, Fang He¹⁰, Xiaofei Shi¹¹, Xiafei Xin¹², Fei Xiao¹³, Hui Xiao¹³, Yuhua Jia¹³, Minjun Wang¹³, Lijun He¹³, Rui Bai¹³, Xiyao Huang¹³, Bing Wu¹³ and Zhanguo Li¹⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁶The First Hospital of Jiaxing, Jiaxing, China, ⁷The 264th Hospital of the PLA, Taiyuan, China, ⁸The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁰Central Hospital of Sui Ning, Sichuan, Suining, China, ¹¹The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹²Ningbo First Hospital, Zhejiang, Ningbo, China, ¹³Gothic Internet Technology Corporation, Shanghai, China, ¹⁴Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 lower than 2.6 (remission) or below 3.2 (low disease activity), is the main management strategy. The Smart System of…
Abstract Number: 2884 • 2017 ACR/ARHP Annual Meeting
A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁸University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Systemic sclerosis (SSc) is characterized in part by chronic activation of the innate immune system with fibrosis. Anabasum is a non-immunosuppressive, synthetic, orally administered…
Abstract Number: 2953 • 2017 ACR/ARHP Annual Meeting
Drivers of Satisfaction with Care in Lupus
Bhavika Sethi¹, Ailda Nika², Winston Sequeira³, Joel A. Block⁴, Sergio Toloza⁵, Ana Bertoli⁶, Ivana Blazevic⁷, Luis M. Vilá⁸, Ioana Moldovan⁹, Karina Torralba¹⁰, Davide Mazzoni¹¹, Elvira Cicognani¹¹, Sarfaraz Hasni¹², Berna Goker¹³, Seminur Haznedaroglu¹³, Josiane Bourré-Tessier¹⁴, Sandra V. Navarra¹⁵, Chi Chiu Mok¹⁶, Ann Clarke¹⁷, Michael Weisman¹⁸, Daniel J. Wallace¹⁹ and Meenakshi Jolly³, ¹University of Birmingham, Birmingham, United Kingdom, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Division of Rheumatology, Rush University Medical Center, Chicago, IL, ⁵Rheumatology, Hospital San Juan Batista, Catamarca, Argentina, Catamarca, Argentina, ⁶Instituto Reumatológico Strusberg, Córdoba, Argentina, ⁷Rheumatology, Universidad de Buenos Aires, Buenos Aires, Argentina, ⁸Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁹Rheumatology, Beaver Medical Group, Redlands, CA, ¹⁰Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, ¹¹Department of Psychology, University of Bologna, Bologna, Italy, ¹²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ¹³Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, ¹⁴Rheumatology, University of Montreal, Montreal, QC, Canada, ¹⁵Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹⁶Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ¹⁷Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ¹⁸Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, ¹⁹Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Although survival in SLE has improved, quality of life (QOL) remains poor. Physicians aim to reduce suffering and improve health outcomes, while maximizing efficiency…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].